A promising biologic candidate can still carry immunosafety and immunogenicity risks that may affect its development potential. Identifying these risks earlier can support better-informed decisions before progressing toward the clinic.
Assessing risk earlier
Lonza combines in silico prediction with human-relevant in vitro testing to evaluate immunosafety and immunogenicity and help identify potential liabilities earlier.
Assessment can provide insight into:
- In silico identification of potential T-cell epitopes and HLA-binding liabilities
- T-cell activation and cytokine responses using human-relevant in vitro assays
- Innate immune responses and potential immunotoxicity risks
- Sequence liabilities that may inform humanization, deimmunization or protein engineering strategies
Read the article to learn how early immunosafety and immunogenicity assessment can help de-risk biologic development.
